Immunovant, Inc.
IMVT · Nasdaq · United States
Share price · IMVT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IMVT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026+15.1%
- 6 Nov 2026+7.5%
Nothing announced by IMVT that day or the session before.
- 8 Oct 2026-5.6%
Nothing announced by IMVT that day or the session before.
- 23 Sep 2026-7.4%
- Roivant Sciences Ltd.: Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus ErythematosusROIV -3.7%
- 20 May 2026+35.3%
Nothing announced by IMVT that day or the session before.
- 8 May 2026+6.3%
Nothing announced by IMVT that day or the session before.
- 17 Apr 2026+7.1%
Nothing announced by IMVT that day or the session before.
- 23 Mar 2026+6.1%
Nothing announced by IMVT that day or the session before.
- 6 Feb 2026+12.4%
Nothing announced by IMVT that day or the session before.
Share of unusual movement by asset
For each asset, the share of IMVT's own-move activity since 15 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Imeroprubartevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 6% |
| Sessions with no dated event | — | 93% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | FcRnMonoclonal antibody | Rheumatoid ArthritisMyasthenia GravisGraves' DiseaseChronic Inflammatory Demyelinating PolyneuropathySjögren's Disease |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
2028 (3)
2030 (1)
March 2030 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $85M | $722M | $97M-$83M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $143M | $798M | $153M-$124M operating cash flow | report ↗ |
| 2025-Q4 | — | $99M | $995M | $111M-$92M operating cash flow | report ↗ |
| 2025-Q3 | — | $114M | $522M | $127M-$103M operating cash flow | report ↗ |
| 2025-Q2 | — | $101M | $599M | $121M-$117M operating cash flow | report ↗ |
| 2024-Q4 | — | $95M | $375M | $111M-$100M operating cash flow | report ↗ |
| 2024-Q3 | — | $97M | $473M | $109M-$89M operating cash flow | report ↗ |
| 2024-Q2 | — | $75M | $560M | $87M-$76M operating cash flow | report ↗ |
| 2023-Q4 | — | $48M | $691M | $51M-$47M operating cash flow | report ↗ |
| 2023-Q3 | — | $48M | $270M | $59M-$60M operating cash flow | report ↗ |
| 2023-Q2 | — | $51M | $330M | $74M-$47M operating cash flow | report ↗ |
| 2022-Q4 | — | $42M | $433M | $63M-$46M operating cash flow | report ↗ |
| 2022-Q3 | — | $38M | $406M | $48M-$20M operating cash flow | report ↗ |
| 2022-Q2 | — | $28M | $427M | $40M-$66M operating cash flow | report ↗ |
| 2021-Q4 | — | $30M | $527M | $41M-$32M operating cash flow | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | — | $457M | $902M | $126M-$407M operating cash flow | report ↗ |
View 5 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $361M | $714M | $103M-$376M operating cash flow | report ↗ |
| 2024-FY | — | $213M | $635M | $65M-$214M operating cash flow | report ↗ |
| 2023-FY | — | $160M | $377M | $53M-$188M operating cash flow | report ↗ |
| 2022-FY | — | $102M | $494M | $39M-$106M operating cash flow | report ↗ |
| 2021-FY | — | — | $400M | $27M-$83M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($350.0M), 61 sales ($16.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-11 | Pande Atul · director | Option exercise | 3,000 | $8.43 | $25K | Form 4 |
| 2026-11-11 | Pande Atul · director | Open-market sale | 3,000 | $36.00 | $108K | Form 4 |
| 2026-11-11 | Pande Atul · director | Option exercise (derivative) | 3,000 | — | — | Form 4 |
| 2026-10-28 | Girao Tiago · Chief Financial Officer | Open-market sale | 6,606 | $28.50 | $188K | Form 4 |
| 2026-10-21 | Stout Jay S · Chief Technology Officer | Open-market sale | 2,595 | $28.94 | $75K | Form 4 |
| 2026-10-07 | Gloria Melanie · Chief Operating Officer | Open-market sale | 2,241 | $32.06 | $72K | Form 4 |
| 2026-10-07 | Van Tuyl Christopher · Chief Legal Officer | Open-market sale | 1,327 | $32.06 | $43K | Form 4 |
| 2026-10-07 | Stout Jay S · Chief Technology Officer | Open-market sale | 2,213 | $32.06 | $71K | Form 4 |